Drugs · acquisition-cost intelligence
Ambien CR
zolpidem tartrate· ingredient zolpidemBenzodiazepine related drugs· ZOLPIDEM TARTRATE 12.5 mg/1; ZOLPIDEM TARTRATE 6.25 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.11608
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-06-112026-05-20
Same-ingredient options by acquisition cost
Other zolpidem products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Ambien | $0.03392 | −$0.08220 |
| Zolpidem | $0.03392 | −$0.08220 |
| zolpidem tartrate | $5.63 | +$5.51 |
| zolpidem tartrate | $7.96 | +$7.84 |
Medicare Part D coverage · CY2026
On 102 plan formularies · typical tier 2
Prior auth 30% · Step therapy 0% · Quantity limit 95% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.